We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| IDEAYA Biosciences Inc | NASDAQ:IDYA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 41.49 | 16.60 | 65.96 | 0 | 09:09:38 |
From May 2022 to May 2024
By Dean Seal
IDEAYA Biosciences Inc. said Monday that U.S. regulators granted fast-track designation to its development program evaluating the combination of two drugs for the treatment of metastatic uveal melanoma.
The oncology company said the U.S. Food and Drug Administration granted the designation for a program looking at darovasertib, a potential first-in-class protein kinase C inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor.
The designation facilitates the development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
IDEAYA is currently targeting a potential registration-enabling trial for the combination in the first quarter of 2023.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 05, 2022 07:00 ET (12:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year IDEAYA Biosciences Chart |
1 Month IDEAYA Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
